Autolus Therapeutics (AUTL) Research & Development (2017 - 2025)
Autolus Therapeutics posted quarterly Research & Development of $35.6 million for Q4 2025, up 15.58% year-on-year from $30.8 million in Q4 2024, and up 27.75% on a QoQ basis from $27.9 million in Q3 2025.
Autolus Therapeutics (AUTL) has 9 years of Research & Development data on file, last reported at $35.6 million in Q4 2025.
- For the quarter ending Q4 2025, Research & Development rose 15.58% year-over-year to $35.6 million; the trailing twelve-month figure through Dec 2025 stood at $117.7 million (down 14.99% YoY), and the FY2025 full-year result was $117.7 million, down 14.99% from the prior year.
- Research & Development for Q4 2025 stood at $35.6 million, up from $27.9 million in the prior quarter.
- Across five years, Research & Development topped out at $206.0 million in Q4 2021 and bottomed at -$32.3 billion in Q3 2021.
- The 5-year median for Research & Development is $30.8 million (2022), against an average of -$1.6 billion.
- Peak annual rise in Research & Development reached 431.9% in 2021, while the deepest fall reached 96364.72% in 2021.
- A 5-year view of Research & Development shows it stood at $206.0 million in 2021, then sank by 96.34% to $7.5 million in 2022, then surged by 397.39% to $37.5 million in 2023, then retreated by 17.88% to $30.8 million in 2024, then increased by 15.58% to $35.6 million in 2025.
- The last three Research & Development figures came in at $35.6 million (Q4 2025), $27.9 million (Q3 2025), and $27.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 1.54 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -2.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Autolus Therapeutics | - | - | -1.04 Mn | 35.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 35.63 Mn |
| Sep 30, 2025 | 27.89 Mn |
| Jun 30, 2025 | 27.43 Mn |
| Mar 31, 2025 | 26.73 Mn |
| Dec 31, 2024 | 30.83 Mn |
| Sep 30, 2024 | 40.32 Mn |
| Jun 30, 2024 | 36.61 Mn |
| Mar 31, 2024 | 30.67 Mn |
| Dec 31, 2023 | 37.54 Mn |
| Sep 30, 2023 | 32.32 Mn |
| Jun 30, 2023 | 33.23 Mn |
| Mar 31, 2023 | 27.39 Mn |
| Dec 31, 2022 | 7.55 Mn |
| Sep 30, 2022 | 31.49 Mn |
| Jun 30, 2022 | 30.79 Mn |
| Mar 31, 2022 | 28.37 Mn |
| Dec 31, 2021 | 205.99 Mn |
| Sep 30, 2021 | -32.29 Bn |
| Jun 30, 2021 | 32.13 Mn |
| Mar 31, 2021 | -30.73 Mn |
| Dec 31, 2020 | 38.73 Mn |
| Sep 30, 2020 | 33.55 Mn |
| Jun 30, 2020 | 31.33 Mn |
| Mar 31, 2020 | -31.29 Mn |
| Jun 30, 2019 | -26.17 Mn |
| Mar 31, 2019 | -22.57 Mn |
| Sep 30, 2018 | -10.10 Mn |
| Jun 30, 2018 | -8.86 Mn |
| Mar 31, 2018 | -11.63 Mn |
| Dec 31, 2017 | 5.56 Mn |